About Florida Cancer Specialists & Research Institute, LLC: (Homepage)
Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Celebrating its 40th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
Tien Do, MD joins FCS Tallahassee Cancer Center
September 6th 2023Florida Cancer Specialists & Research Institute, LLC is pleased to welcome hematologist and medical oncologist Tien Do, MD to the statewide practice. He is providing care to patients at the FCS Tallahassee Cancer Center, 2351 Phillips Road, Tallahassee, FL.
Precision Medicine at Scale is Here
August 7th 2023Lucio Gordan, MD, President & Managing Physician of Florida Cancer Specialists & Research Institute, LLC, talked with Kevin Keegan, General Manager of Oncology Business with Illumina, about how FCS is bringing precision oncology through analysis of real-world data, innovative technology and research to cancer patients being treated in community settings.
Chemotherapy Drug Shortages Affecting Cancer Patients in Florida, Across the Country
July 27th 2023The platinum drugs, carboplatin and cisplatin, known for effectively treating lung, head and neck, breast, ovarian, gastric, bladder and testicular cancers, have been in short order for the past few months.
Time to Treatment Matters After a Cancer Diagnosis
July 19th 2023Finding a comprehensive cancer care provider that is able to provide patients with swift and easy access to the highest-quality diagnosis and treatment planning is essential to reducing stress and ensuring patients achieve the best possible outcomes.
Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLC
Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.
Advanced NSCLC: Interpreting Data From the POSEIDON Trial
A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.
Role for IO Therapy in Advanced NSCLC With Concomitant KRAS and KEAP1/STK11 Mutations
Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.
Combination Chemo + IO Therapy in Advanced Non–Small Cell Lung Cancer
A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.
Selecting Therapy for Advanced NSCLC Based on PD-L1 and NGS Testing
Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.
Factors in Selecting IO Therapy for Patients With Advanced NSCLC
Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.
Adjuvant Treatment Strategies in Resectable Non–Small Cell Lung Cancer
Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.
Key Decisionmaking Factors in Resectable Non–Small Cell Lung Cancer
Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).